[7]Weidinger S, . Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2024 Nov 8:S0091-6749(24)01175-8. [8]Br...
[5]Andrew Blauvelt, et al. Impact of amlitelimab (an anti-OX40 Ligand antibody) on Clinical Outcome Assessments for atopic dermatitis: results from the 52-week STREAM-AD phase 2b study in adults with moderate-to-severe atopic dermat...
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitisAmlitelimabbiologicatopic dermatitiseczemaOX40 ligandinflammationT cellsimmunologyimmune dysregulationbarrier dysfunctionAmlitelimab, a fully human nondepleting mAb targeting...
The first phase I clinical trial using a murine antihuman OX40 mAb has been initiated in patients with advanced cancer. This trial is essentially a proof of concept, as neutralizing human antimouse antibodies are expected to be limiting, and a humanized or fully human antibody should be pursued...
announced today that its IND application for IBI101, a recombinant fully human anti-OX40 monoclonal antibody (mAb) drug candidate, has been approved by the US Food & Drug Administration (FDA), and plans to initiate the US phase I clinical ...
demonstrated expression of OX40, as well as PD-1 and CTLA-4, on T cells isolated from the tumor compared to blood, suggesting that targeting these pathways independently or in combination may result in therapeutic advantages23. A first in human phase I clinical trial with this antibody to OX...
Treatment with IMG-007, the only clinical-stage nondepleting anti-OX40 monoclonal antibody (mAb), led to rapid, marked, and durable improvement of skin signs in patients with atopic dermatitis (AD). O...
目的探讨OX40在新诊断2型糖尿病(T2DM)患者外周循环滤泡辅助性T细胞(cTfh)表面的表达特性及其与胰岛素抵抗(IR)的相关性。 方法选取2020年11月至2021年12月于苏州大学附属第一医院内分泌科住院的新诊断T2DM患者,并选取同时期体检中心的健康志愿者作为对照。测量研究对象身高、体重并计算体重指数(BMI),收集研究对象空腹...
(CTLs) response in TME. On top of it, this ISV can exert an abscopal effect and synergize with an anti-PD1 antibody, converting so-called immune-desert or “cold” phenotype into “hot” inflamed tumors. Altogether, we find thatLactococcus lactishas the potential to be a platform for ...
5.The anti-OX40 antibody of claim 3, which is an IgG. 6.The anti-OX40 antibody of claim 5, which is an IgG1. 7.The anti-OX40 antibody of claim 3 comprising a kappa light chain constant region. 8.The anti-OX40 antibody of claim 1 which comprises a heavy chain having an amino ...